Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04536077 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | terminated | Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 |
| clinicaltrials |
| NCT04517448 | Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy(EQLVCPAL) | terminated | — | 31 | Centre Hospitalier de la côte BasqueOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT03716596 | SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients(CISPD-2) | terminated | Phase 1 | 8 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05188586 | New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)(NODMED) | terminated | N/A | 26 | ClearNote HealthINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT02798003 | Food Reward in Cachexia Induced by Acute or Chronic Disease | terminated | — | 44 | Maastricht University Medical CenterOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00113256 | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | terminated | Phase 2 / Phase 3 | 39 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03956056 | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | terminated | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | terminated | Phase 1 | 3 | Hoffmann-La RocheINDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 78 | ADC Therapeutics S.A.INDUSTRY | 3 | Jun 13, 2024 | clinicaltrials |
| NCT03492164 | In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer | terminated | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT04843306 | Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients | terminated | N/A | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT02902484 | Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05116917 | Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.(INFLUENCE) | terminated | Phase 2 | 19 | Herlev HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX(SLC-0111-17-01) | terminated | Phase 1 / Phase 2 | 6 | British Columbia Cancer AgencyOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | terminated | Phase 1 / Phase 2 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | May 22, 2024 | clinicaltrials |
| NCT04698915 | Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer | terminated | Phase 2 | 177 | Galera Therapeutics, Inc.INDUSTRY | 4 | May 21, 2024 | clinicaltrials |
| NCT06164691 | Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer | terminated | N/A | 2 | Matthew Neal MDOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04390243 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | terminated | Phase 2 | 6 | Academic and Community Cancer Research UnitedOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours(MYCure) | terminated | Phase 1 / Phase 2 | 22 | Peptomyc S.L.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03848182 | Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer | terminated | Phase 2 | 10 | Albert Einstein College of MedicineOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT06371716 | Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions | terminated | N/A | 45 | IRCCS San RaffaeleOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06341725 | EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging | terminated | — | 2 | Paolo Giorgio Arcidiacono, MDOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04300114 | A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | terminated | Phase 3 | 5 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03724435 | Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry(ARRAY) | terminated | — | 21 | Focused Ultrasound FoundationOTHER | 4 | Mar 18, 2024 | clinicaltrials |
| NCT03519308 | A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer | terminated | Early Phase 1 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00322712 | INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer | terminated | — | 12 | University of New MexicoOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT02722616 | Ultrasound Monitoring of Abdominal Soft Tissue | terminated | N/A | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03397342 | MRI Only Radiation Therapy With CPAP | terminated | N/A | 5 | Albert Einstein College of MedicineOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | terminated | Phase 1 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04592861 | Carbon Ion RT for Locally Advanced Pancreatic Cancer | terminated | Phase 3 | 5 | Albert Einstein College of MedicineOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT04452396 | CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia | terminated | N/A | 7 | Barts & The London NHS TrustOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05193604 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma | terminated | Phase 1 | 29 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 8, 2023 | clinicaltrials |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 23 | Albert Einstein College of MedicineOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04637698 | OH2 Oncolytic Viral Therapy in Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 5 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(RELIANT) | terminated | Phase 3 | 43 | Corcept TherapeuticsINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 7 | Zhen Wang, MDOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT03649321 | Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 9 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 8, 2024source: clinicaltrials